Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections

Peter B. Jahrling, T. W. Geisbert, J. B. Geisbert, J. R. Swearengen, M. Bray, N. K. Jaax, J. W. Huggins, J. W. LeDuc, C. J. Peters

Research output: Contribution to journalArticle

227 Scopus citations

Abstract

A passive immunization strategy for treating Ebola virus infections was evaluated using BALB/c mice, strain 13 guinea pigs, and cynomolgus monkeys. Guinea pigs were completely protected by injection of hyperimmune equine IgG when treatment was initiated early but not after viremia had developed. In contrast, mice were incompletely protected even when treatment was initiated on day 0, the day of virus inoculation. In monkeys treated with one dose of IgG on day 0, onset of illness and viremia was delayed, but all treated animals died. A second dose of IgG on day 5 had no additional beneficial effect. Pretreatment of monkeys delayed onset of viremia and delayed death several additional days. Interferon-α2b (2 x 107 IU/kg/day) had a similar effect in monkeys, delaying viremia and death by only several days. Effective treatment of Ebola infections may require a combination of drugs that inhibit vital replication in monocyte/macrophage-like cells while reversing the pathologic effects (e.g, coagulopathy) consequent to this replication.

Original languageEnglish (US)
Pages (from-to)S224-S234
JournalJournal of Infectious Diseases
Volume179
Issue numberSUPPL. 1
DOIs
StatePublished - 1999
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections'. Together they form a unique fingerprint.

  • Cite this

    Jahrling, P. B., Geisbert, T. W., Geisbert, J. B., Swearengen, J. R., Bray, M., Jaax, N. K., Huggins, J. W., LeDuc, J. W., & Peters, C. J. (1999). Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. Journal of Infectious Diseases, 179(SUPPL. 1), S224-S234. https://doi.org/10.1086/514310